Lupin launches generic Trilipix delayed-release capsules 45 mg & 135 mg in the US

Lupin’s US subsidiary, Lupin Pharmaceuticals has launched its generic Fenofibric acid delayed-release capsules 45 mg and 135 mg. Lupin had earlier received final approval from the US FDA for the same.

Lupin’s Fenofibric acid delayed-release capsules 45 mg and 135 mg are the generic equivalent of AbbVie Trilipix delayed-release capsules 45 mg & 135 mg strengths are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.

Trilipix delayed-release capsules 45 mg & 135 mg strengths had annual US sales of approximately $ 449.5 million.

EP News Bureau – Mumbai